Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study

doi:10.1093/neuonc/nox107

. 2017 Sep 1;19(9):1279-1280.

doi: 10.1093/neuonc/nox107.

Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study

Tabitha Cooney¹, Adam Lane¹, Ute Bartels¹, Eric Bouffet¹, Stewart Goldman¹, Sarah E S Leary¹, Nicholas K Foreman¹, Roger J Packer¹, Alberto Broniscer¹, Jane E Minturn¹, Chie-Schin Shih¹, Murali Chintagumpala¹, Tim Hassall¹, Nicholas G Gottardo¹, Hetal Dholaria¹, Lindsey Hoffman¹, Brooklyn Chaney¹, Joshua Baugh¹, Renee Doughman¹, James L Leach¹, Blaise V Jones¹, Maryam Fouladi¹, Katherine E Warren¹, Michelle Monje¹

Affiliations

Affiliation

¹ Departments of Neurology, Neurosurgery and Pediatrics, Lucile Packard Children's Hospital at Stanford, Stanford, California; Department of Pediatrics, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Canada; Departments of Hematology-Oncology, Neuro-Oncology & Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Hematology/Oncology, Seattle Children's Hospital, Seattle, Washington; Departments of Pediatrics, University of Colorado and Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Denver, Colorado; Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, Washington D.C.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Section of Pediatric Hematology/Oncology, Riley Children's Hospital, Indianapolis, Indiana; Department of Pediatrics, Texas Children's Hospital, Houston, Texas; Lady Cilento Children's Hospital, Brisbane, Australia; Princess Margaret Hospital for Children and Telethon Kid's Institute, Subiaco, Australia; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.

PMID: 28821206
PMCID: PMC5570207
DOI: 10.1093/neuonc/nox107

Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study

Tabitha Cooney et al. Neuro Oncol. 2017.

. 2017 Sep 1;19(9):1279-1280.

doi: 10.1093/neuonc/nox107.

Authors

Affiliation

¹ Departments of Neurology, Neurosurgery and Pediatrics, Lucile Packard Children's Hospital at Stanford, Stanford, California; Department of Pediatrics, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Canada; Departments of Hematology-Oncology, Neuro-Oncology & Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Hematology/Oncology, Seattle Children's Hospital, Seattle, Washington; Departments of Pediatrics, University of Colorado and Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Denver, Colorado; Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, Washington D.C.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Section of Pediatric Hematology/Oncology, Riley Children's Hospital, Indianapolis, Indiana; Department of Pediatrics, Texas Children's Hospital, Houston, Texas; Lady Cilento Children's Hospital, Brisbane, Australia; Princess Margaret Hospital for Children and Telethon Kid's Institute, Subiaco, Australia; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.

PMID: 28821206
PMCID: PMC5570207
DOI: 10.1093/neuonc/nox107

No abstract available

PubMed Disclaimer

Cited by

Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, Spratt DE, Leonard M, Qin T, Zhao L, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C. Gits HC, et al. Acta Neuropathol Commun. 2018 Jul 26;6(1):67. doi: 10.1186/s40478-018-0570-9. Acta Neuropathol Commun. 2018. PMID: 30049282 Free PMC article.
High expression of HOXA4 in patients with glioma indicates unfavorable clinical outcomes.
Yu Z, Liu Z, Lian X, Cheng X, Liu B, Zhang B, Wang H, Wang J, Li A, Ren Z, Pang B, Qian R, Gao Y. Yu Z, et al. Cell Cycle. 2022 Nov;21(22):2387-2402. doi: 10.1080/15384101.2022.2096715. Epub 2022 Jul 19. Cell Cycle. 2022. PMID: 35852388 Free PMC article.
Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells.
Bonner ER, Waszak SM, Grotzer MA, Mueller S, Nazarian J. Bonner ER, et al. Neuro Oncol. 2021 Apr 12;23(4):542-556. doi: 10.1093/neuonc/noaa283. Neuro Oncol. 2021. PMID: 33336683 Free PMC article. Review.
Stemming the growth of pediatric gliomas through histone modification.
Fults DW. Fults DW. Neuro Oncol. 2021 Mar 25;23(3):341-342. doi: 10.1093/neuonc/noaa302. Neuro Oncol. 2021. PMID: 33470409 Free PMC article. No abstract available.
Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas.
Keane L, Cheray M, Saidi D, Kirby C, Friess L, Gonzalez-Rodriguez P, Gerdes ME, Grabert K, McColl BW, Joseph B. Keane L, et al. Neurooncol Adv. 2021 Jul 5;3(1):vdab096. doi: 10.1093/noajnl/vdab096. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34485907 Free PMC article.

See all "Cited by" articles

References

1. Garzón M, García-Fructuoso G, Guillén A, Suñol M, Mora J, Cruz O. Brain stem tumors in children and adolescents: single institutional experience. Childs Nerv Syst. 2013;29(8):1321–1331. - PubMed
1. Salloum R, DeWire M, Lane A et al. . Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with bevacizumab-based therapy at diagnosis. J Neurooncol. 2015;121(3):591–598. - PubMed
1. Vallero SG, Bertin D, Basso ME, Pittana LS, Mussano A, Fagioli F. Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience. Childs Nerv Syst. 2014;30(6):1061–1066. - PubMed
1. Wolffe JE, Rytting ME, Vats TS et al. . Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012;106(2):391–397. - PMC - PubMed
1. Packer RJ. Brain stem gliomas: therapeutic options at time of recurrence. Pediatr Neurosurg. 1996;24(4):211–216. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

[1] Garzón M, García-Fructuoso G, Guillén A, Suñol M, Mora J, Cruz O. Brain stem tumors in children and adolescents: single institutional experience. Childs Nerv Syst. 2013;29(8):1321–1331. - PubMed

[2] Garzón M, García-Fructuoso G, Guillén A, Suñol M, Mora J, Cruz O. Brain stem tumors in children and adolescents: single institutional experience. Childs Nerv Syst. 2013;29(8):1321–1331. - PubMed

[3] Salloum R, DeWire M, Lane A et al. . Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with bevacizumab-based therapy at diagnosis. J Neurooncol. 2015;121(3):591–598. - PubMed

[4] Salloum R, DeWire M, Lane A et al. . Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with bevacizumab-based therapy at diagnosis. J Neurooncol. 2015;121(3):591–598. - PubMed

[5] Vallero SG, Bertin D, Basso ME, Pittana LS, Mussano A, Fagioli F. Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience. Childs Nerv Syst. 2014;30(6):1061–1066. - PubMed

[6] Vallero SG, Bertin D, Basso ME, Pittana LS, Mussano A, Fagioli F. Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience. Childs Nerv Syst. 2014;30(6):1061–1066. - PubMed

[7] Wolffe JE, Rytting ME, Vats TS et al. . Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012;106(2):391–397. - PMC - PubMed

[8] Wolffe JE, Rytting ME, Vats TS et al. . Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012;106(2):391–397. - PMC - PubMed

[9] Packer RJ. Brain stem gliomas: therapeutic options at time of recurrence. Pediatr Neurosurg. 1996;24(4):211–216. - PubMed

[10] Packer RJ. Brain stem gliomas: therapeutic options at time of recurrence. Pediatr Neurosurg. 1996;24(4):211–216. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study

Affiliation

Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study

Authors

Affiliation

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources